local_hospital

University Childrens Hospital Queen Fabiola

Address
lock Available on a paid plan

Digestive System Diseases and Pediatric Gastroenterology

At University Childrens Hospital Queen Fabiola, clinical research in gastro-enterology focuses on inflammatory bowel disease in children and adolescents, especially Crohn's disease and ulcerative colitis. These studies are designed to assess new treatment options and better understand how well therapies control symptoms and support long-term disease remission.

  • Research on pediatric moderately to severely active Crohn's disease
  • Studies in pediatric and adolescent ulcerative colitis
  • Evaluation of therapies aimed at improving clinical remission and digestive health outcomes

This work reflects a strong interest in improving care for young patients with chronic digestive system diseases, with attention to both symptom control and treatment effectiveness.

Congenital, Hereditary, and Neonatal Diseases

The site also supports research in rare congenital and hereditary diseases, including hypophosphatasia in pediatric participants. These trials aim to test whether new therapies can improve disease-related outcomes and provide better options for children living with uncommon metabolic conditions.

  • Studies in pediatric hypophosphatasia
  • Assessment of treatment benefits in children who have not previously received standard enzyme therapy
  • Research focused on improving radiographic outcomes and overall disease management

This area highlights the hospital’s role in advancing care for rare pediatric disorders where effective treatment choices are especially important.

Neoplasms and Pediatric Neuro-Oncology

Clinical trials at this Brussels site include research on medulloblastoma, a pediatric brain tumor, with a focus on comparing treatment strategies and understanding their impact on long-term outcomes. The goal is to improve both disease control and the child’s future quality of life, including neurocognitive development.

  • Studies in newly diagnosed, non-metastatic medulloblastoma
  • Evaluation of treatment approaches for SHH-activated tumor subtypes
  • Research measuring neurocognitive outcomes after therapy

This research area shows a commitment to pediatric oncology that looks beyond tumor response and considers the child’s development and daily functioning.

Skin and Connective Tissue Diseases in Broader Pediatric Care

Although the main trial activity is concentrated in digestive and rare disease research, the site’s therapeutic profile also includes skin and connective tissue diseases, reflecting a broader clinical research interest in pediatric conditions that may affect growth, structure, and overall health.

  • Coverage of skin and connective tissue diseases within the site’s therapeutic portfolio
  • Participation in research across multiple pediatric disease areas
  • Support for studies that may improve diagnosis and treatment planning in children

Together with the hospital’s other studies, this area adds to a diverse research environment led by experienced investigators in pediatric clinical trials.

Site Overview

assignment
81
connected trials
corporate_fare
54
sponsors
science
152
IMPs

Activity Indicator

Last 6 months

3
Trials started
-40% vs previous period.
5
Trials started 6–12 months ago
81
Total trials linked
Highly Active
trending_downDeclining-40%
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 19 therapeutic areas and 15 of 152 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 151 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
45
Sponsors (total)
54
Active sponsors
33

Sponsor Network

Top 33 by active trials.

lock +32 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +15 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 307 other sites in Belgium

description
Trial volume
81
Outperforms 93% of sites
public
Therapeutic diversity
19areas
Outperforms 94% of sites
groups
Sponsor diversity
54sponsors
Outperforms 94% of sites

Therapeutic Area Benchmark — Belgium

Select a therapeutic area to compare against other sites in Belgium.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Belgium

Market Share

Country: Belgium

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in University Childrens Hospital Queen Fabiola

lock Showing 1 of 81 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)Apcintex LimitedPhase IINot RecruitingNov 2023Jan 2025

IMP list

lock Showing 1 of 152 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cyclophosphamide14Unknown2014-03-272025-12-24

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.